**Ahonen 1997** Ahonen, Jouni, Klaus T. Olkkola, and Pertti J. Neuvonen.  (1997). Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. *European journal of clinical pharmacology* 51.5, 415-419.

**Brammer 1990** Brammer, K. W., P. R. Farrow, and J. K. Faulkner.  (1990). Pharmacokinetics and tissue penetration of fluconazole in humans. *Reviews of infectious diseases* 12.Supplement_3, S318-S326.

**Brammer 1991** Brammer, K. W., Coakley, A. J., Jezequel, S. G., & Tarbit, M. H.  (1991). The disposition and metabolism of [14C] fluconazole in humans. *Drug metabolism and disposition* 19.4, 764-767.

**Charoo 2014** Charoo, N., Cristofoletti, R., Graham, A., Lartey, P., Abrahamsson, B., Groot, D. W., ... & Dressman, J. (2014). Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole. *Journal of pharmaceutical sciences*, *103*(12), 3843-3858.

**Cristofoletti 2016** Cristofoletti, R., Charoo, N. A., & Dressman, J. B. (2016). Exploratory investigation of the limiting steps of oral absorption of fluconazole and ketoconazole in children using an in silico pediatric absorption model. *Journal of pharmaceutical sciences*, *105*(9), 2794-2803.

**Debruyne 1993** Debruyne, D., & Ryckelynck, J. P. (1993). Clinical pharmacokinetics of fluconazole. *Clinical pharmacokinetics*, *24*(1), 10-27.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. (2016). Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. *CPT Pharmacometrics Syst Pharmacol*. Oct;5(10), 516-531.

**Meyer 2012** Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. (2012). Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. *Drug Metab Dispos*. May;40(5), 892-901.

**Nishimura 2003** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi.* May;123(5), 369-75.

**Palkama 1998** Palkama, V. J., Isohanni, M. H., Neuvonen, P. J., & Olkkola, K. T. (1998). The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. *Anesthesia & Analgesia*, *87*(1), 190-194.

**Ripa 1993** Ripa, S., Ferrante, L., & Prenna, M. (1993). Pharmacokinetics of fluconazole in normal volunteers. *Chemotherapy*, *39*(1), 6-12.

**Sakaeda 2005** Sakaeda, T., Iwaki, K., Kakumoto, M., Nishikawa, M., Niwa, T., Jin, J. (2005). Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. *J Pharm Pharmacol*, *57*, 759-764.

**Shiba 1990** Shiba, K., Saito, A., & Miyahara, T. (1990). Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. *Clinical therapeutics*, *12*(3), 206-215.

**Sobue 2004** Sobue, S., Tan, K., Layton, G., Eve, M., & Sanderson, J. B. (2004). Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. *British journal of clinical pharmacology*, *58*(1), 20-25.

**Thorpe 1990** Thorpe, J. E., Baker, N., & Bromet-Petit, M. (1990). Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. *Antimicrobial agents and chemotherapy*, *34*(10), 2032-2033.

**Varhe 1996** Varhe, A., Olkkola, K. T., & Neuvonen, P. J. (1996). Effect of fluconazole dose on the extent of fluconazole‐triazolam interaction. *British journal of clinical pharmacology*, *42*(4), 465-470.

**Watt 2018** Watt, K. M., Cohen‐Wolkowiez, M., Barrett, J. S., Sevestre, M., Zhao, P., Brouwer, K. L., & Edginton, A. N. (2018). Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. *CPT: pharmacometrics & systems pharmacology*, *7*(10), 629-637.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn.* 34(3), 401-431.

**Yeates 1994** Yeates, R. A., Ruhnke, M., Pfaff, G., Hartmann, A., Trautmann, M., & Sarnow, E. (1994). The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients. *British journal of clinical pharmacology*, *38*(1), 77-79.
